What is the current stock price of AbCellera Biologics Inc. (ABCL)?

As of the latest market data, AbCellera Biologics Inc. (ABCL) is trading at $3.54. The stock has seen a gain of 2.91% today.

Does AbCellera Biologics Inc. (ABCL) pay a dividend?

Based on current data, AbCellera Biologics Inc. does not have a confirmed active dividend policy.

What is the market cap of AbCellera Biologics Inc.?

The current market capitalization of AbCellera Biologics Inc. (ABCL) is approximately unavailable.

ABCL

AbCellera Biologics Inc.·Healthcare

3.54

2.907%(+0.10)

Market Closed

3.71

4.802%(+0.17)

After Hours

Last Updated: — ET

52W L: $1.9452W H: $6.51

ABCL NEWS

businesswire.com

Apr 1

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026.

seekingalpha.com

Mar 23

AbCellera Biologics Inc. (ABCL) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

seekingalpha.com

Mar 6

AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

defenseworld.net

Mar 6

AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says

AbCellera Biologics (NASDAQ: ABCL) is positioning itself as a more pipeline-driven biotechnology company after more than a decade of platform investment, according to comments from Senior Director of Strategic Finance and Investor Relations Martin Hogan at TD Cowen's 46th Annual Health Care Conference. Hogan said AbCellera has spent "something like $1 billion" over roughly 13 years

feeds.benzinga.com

Feb 25

What Sparked AbCellera Biologics To Soar Over 9% After Hours

AbCellera Biologics shares jumped 9.3% after hours to $3.52 following an 83% earnings beat in Q4 2025.

zacks.com

Feb 24

AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.11 per share a year ago.

Company Profile

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Sector

Healthcare

Industry

Biotechnology

Employees

596

IPO Date

2020-12-11

Beta

0.85

Websitewww.abcellera.com↗